Acumen Pharmaceuticals, Inc.
Morocco, Greater Boston, MA
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease by attacking toxic soluble amyloid beta oligomers (AβOs). Its lead program, sabirnetug (ACU193), is a monoclonal antibody designed to selectively neutralize AβOs and is being evaluated in the Phase 2 ALTITUDE-AD trial. The company is also advancing an Enhanced Brain Delivery (EBD™) program that leverages J-Brain Cargo® technology to improve blood–brain barrier penetration and enable subcutaneous dosing. Acumen is headquartered in Newton, Massachusetts and focuses on therapies for early Alzheimer’s disease.
Latest Funding
Announced 2026-03-16
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
2 signals · where the capital is going
Funding corporate operations and ALTITUDE-AD Phase II clinical trial with cash reserves projected through early 2027
investing.com
+1 more capital deployment signal · confidence ratings · source articles
Sign up freeIn the news
Selling to Acumen Pharmaceuticals, Inc.? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Acumen Pharmaceuticals, Inc..
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Acumen Pharmaceuticals, Inc., and who are their main competitors?
Sign up free to ask AI about Acumen Pharmaceuticals, Inc.
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Sands Capital
Lead investor · undisclosed
Tech Stack
WordPress
MySQL
PHP
Key Highlights
AI InsightsCompany continues development of sabirnetug (ACU193) in the Phase 2 ALTITUDE-AD trial and is advancing a subcutaneous formulation with Halozyme's ENHANZE®.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Acumen Pharmaceuticals, Inc.
Selling to Acumen Pharmaceuticals, Inc.? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Acumen Pharmaceuticals, Inc..
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.